Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Loretta J. Nastoupil"'
Autor:
Joseph D. Khoury, Sarah A. Milgrom, Loretta J. Nastoupil, Elizabeth J. Shpall, Jillian R. Gunther, Sattva S. Neelapu, Sairah Ahmed, Raphael E Steiner, Maria Gule-Monroe, Ranjit Nair, Karine A. Al Feghali, Jason R. Westin, Chelsea C. Pinnix, Chitra Hosing, Nathan Fowler, Tommy Sheu, Penny Fang, Bouthaina S. Dabaja, Christopher R. Flowers, Paolo Strati, Yago Nieto
Publikováno v:
Leukemia & Lymphoma. 62:2400-2407
This study aimed to assess the prognostic value of baseline disease distribution for patients with the secondary central nervous system (CNS) diffuse large B-cell lymphoma (DLBCL) treated with chemotherapy and radiation (RT). 44 patients with seconda
Autor:
Erin Taylor, Felipe Samaniego, Loretta J. Nastoupil, Lei Feng, Sattva S. Neelapu, Peter McLaughlin, Fredrick B. Hagemeister, Barbara Pro, Nathan Fowler, Maria Alma Rodriguez, Michelle A. Fanale
Publikováno v:
Leukemia & Lymphoma. 62:58-67
R-FND (rituximab, fludarabine, mitoxantrone, and dexamethasone) can induce molecular remissions in indolent lymphoma. The addition of 90yttrium ibritumomab tiuxetan (90YIT) radioimmunotherapy following first-line induction treatment in patients with
Autor:
Ian W. Flinn, M. Lia Palomba, Sattva S. Neelapu, Peter Martin, Jutta K. Neuenburg, Loretta J. Nastoupil, Nathan Fowler, Raul Mena, Ranjana H. Advani, Darrin M. Beaupre, Karl Eckert, Sven de Vos, Mark Knapp, Sumeet Bhatia, Richard E. Davis, Robert T. Chen, Melannie Co, Jerry Ping
Publikováno v:
British Journal of Haematology
Summary This phase 2 study evaluated the activity and safety of ibrutinib, a Bruton’s tyrosine kinase inhibitor, plus rituximab in adults with previously untreated follicular lymphoma. Patients received once‐daily ibrutinib 560 mg continuously pl
Autor:
Sattva S. Neelapu, David A. Scheinberg, Saber Tadros, Neeraj Jain, E. De Stanchina, Matthew Durant, Jose Baselga Baselga, Lorena Fontan, Eneda Toska, Oliver Weigert, Cassian Yee, Anas Younes, Ahmet Dogan, Ari Melnick, Aaron Y. Chang, Huan Yang, Anja Mottok, Hsia-Yuan Ying, Loretta J. Nastoupil, Chi-Shuen Chu, Stefan Alig, Robert G. Roeder, Giorgio Inghirami, Patrizia Mondello, Man Chun John Ma, Shailbala Singh, Michael R. Green, Sreejoyee Ghosh, Matt Teater
Publikováno v:
Cancer Discov
CREBBP mutations are highly recurrent in B-cell lymphomas and either inactivate its histone acetyltransferase (HAT) domain or truncate the protein. Herein, we show that these two classes of mutations yield different degrees of disruption of the epige
Autor:
Amy A. Ayers, Loretta J. Nastoupil, Mary L Somma, Christopher R. Flowers, Jonathan W. Friedberg, Alix Y L Zackon, Katherine A. Yeager
Publikováno v:
Leuk Lymphoma
Oral therapies have become a common treatment choice for several lymphoid cancers. While therapeutic efficacy and patient preference for this therapy type have been reported, there is a lack of knowledge about its effectiveness for lymphoma in clinic
Autor:
Melody R. Becnel, Andrew M. Evens, Stephen D. Smith, Pooja Mehra, Amrita Desai, Prathima Reddy, Dhruvika Mukhija, Max L. Goldman, Bita Fakhri, James R. Cerhan, Brad S. Kahl, Abhigna Kodali, Jonathon B. Cohen, Brian K. Link, Juan Pablo Alderuccio, Deepa Jagadeesh, Nilanjan Ghosh, Allison M. Winter, Izidore S. Lossos, Thomas M. Habermann, Mohammad Junaid Hussain, Oscar Calzada, Timothy Tiutan, Peter Martin, Loretta J. Nastoupil, Craig A. Portell, Matthew J. Maurer, Brian T. Hill, Paolo Caimi
Publikováno v:
British journal of haematology, vol 184, iss 4
Bendamustine (B) with rituximab (R) is a standard frontline treatment for medically fit follicular lymphoma (FL) patients. The safety and efficacy of maintenance rituximab (MR) after BR induction has not been formally compared to observation for FL,
Autor:
Sattva S. Neelapu, Ann S. LaCasce, Jason R. Westin, C. David Fuller, Zeinab Abou Yehia, Hubert H. Chuang, L. Jeffrey Medeiros, Philippe Armand, Bouthaina S. Dabaja, Christine F. Wogan, Wei Qiao, Jillian R. Gunther, Yasuhiro Oki, William Martin-Doyle, Michelle A. Fanale, Andrea K. Ng, Grace L. Smith, Loretta J. Nastoupil, Mani Akhtari, Chelsea C. Pinnix, Sarah A. Milgrom, Osama Mawlawi
Publikováno v:
Blood Advances. 2:1334-1343
Dose-adjusted rituximab plus etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (DA-R-EPOCH) has produced good outcomes in primary mediastinal B-cell lymphoma (PMBCL), but predictors of resistance to this treatment are unclear. We
Autor:
Jillian R. Gunther, Chelsea C. Pinnix, Yasuhiro Oki, Jason R. Westin, Sarah A. Milgrom, L. Jeffrey Medeiros, Luis Fayad, Ethan B. Ludmir, Loretta J. Nastoupil, Bouthaina S. Dabaja
Publikováno v:
Leukemia & Lymphoma. 59:2896-2903
Treatment strategies and outcomes were assessed in 25 patients with primary breast diffuse large B-cell lymphoma (PB-DLBCL) treated between 1995 and 2016. We specifically investigated the timing of recurrence, and the roles of radiotherapy (RT) and c
Autor:
Hubert H. Chuang, Chelsea C. Pinnix, Donald Hancock, N. George Mikhaeel, Sarah A. Milgrom, Andrew Wirth, Michalis Aristophanous, Mary Pham, Loretta J. Nastoupil, Bouthaina S. Dabaja, Yasuhiro Oki, Ethan B. Ludmir, Michelle A. Fanale, T.Y. Andraos, Jillian R. Gunther
Publikováno v:
Leukemia & Lymphoma. 59:2650-2659
Cardiophrenic lymph nodes (CPLNs) are occasionally involved in Hodgkin lymphoma (HL). We characterized the incidence of CPLN involvement among 169 HL patients and evaluated outcomes after treatment with omission of the CPLN region from the involved-s
Autor:
Michael J. Overman, Francesco Turturro, Sergio Pina-Oviedo, Sattva S. Neelapu, Nathan Fowler, Paolo Strati, Luis Fayad, Yasuhiro Oki, Jason R. Westin, Michael Wang, Loretta J. Nastoupil, Fredrick B. Hagemeister, Alma Rodriguez, Jorge E. Romaguera, L. Jeffrey Medeiros
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 18:e103-e108
Background The optimal management of patients with follicular lymphoma Grade 3 (FLG3) is controversial. Patients and Methods This is a case series of 45 patients with FLG3 treated with first-line R-CHOP (rituximab, cyclophosphamide, doxorubicin, vinc